LANCASTER, Pa - Monday, November 18th 2013 [ME NewsWire]
(BUSINESS WIRE)-- Eurofins Lancaster Laboratories, the global leader in bio/pharmaceutical GMP product testing, and Celsis International Ltd., the global leader in rapid microbial detection systems, announced today that they have entered into a collaboration through which Eurofins Lancaster Laboratories will provide contract rapid microbiology validation and screening services for the Celsis rapid detection technology platform.
The Celsis rapid detection system allows companies to ensure that their products meet microbial specification 60 – 80% faster than traditional methods. The decrease of as many as 7 to 10 days in production cycle times results in reduced inventories and working capital requirements in addition to providing earlier notification of microbial excursions when they occur.
"The pharmaceutical industry has begun to embrace the cost savings that the Celsis method can bring to their operations," said Judy Madden, Vice President of Corporate Development for Celsis. "We’re working with some of the pharmaceutical industry’s leaders to implement the Celsis method for microbial limits and sterility testing but many don’t have the resources or expertise to complete the validation work required before implementation. Eurofins Lancaster Laboratories’ expertise in this area will ensure high-quality validations and streamline the implementation process for our customers.”
With 50 years of delivering outstanding testing services, Eurofins Lancaster Laboratories has a stellar reputation for excellence in service quality and data reliability, enjoys long-standing relationships with many Fortune 500 clients and is part of the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide.
"We are pleased to have expanded our rapid technologies service offerings with the Celsis system in response to this industry need,” said Mark Kaiser, Director of Pharmaceutical Microbiology. "We have the Celsis system fully operational in both our US and Irish facilities, and both sites have initiated validation projects under contract. In addition to these, we anticipate that some of our current client base will move their routine microbiology testing to the Celsis method accelerating product release."
Judy Madden added, "We’re excited that this collaboration will further advance the development of our pharmaceutical initiative by addressing an unmet market need.”
About Eurofins Lancaster Laboratories
A member of Eurofins Scientific’s BioPharma Product Testing Group—the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide—Eurofins Lancaster Laboratories provides comprehensive laboratory services for the world's largest pharmaceutical and biopharmaceutical companies. Founded in 1961, Eurofins Lancaster Laboratories has a global capacity of 330,000 square feet and 1,500 employees.
Eurofins Scientific is the world leader in laboratory testing for food, environment and bio/pharmaceutical products, employing over 14,500 staff in more than 190 laboratories across 37 countries. The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
For more information visit: www.LancasterLabsPharm.com
About Celsis International Ltd.
Celsis International Ltd. is a leading global provider of rapid microbial detection systems used by manufacturers to screen their products for microbial contamination. Celsis has installed over 800 systems in production facilities in more than 60 countries around the world and has relationships with leading companies in the pharmaceutical, consumer product and beverage industries. For more information on the company, visit www.celsis.com/pharma.
Keywords; Celsis, Eurofins, Lancaster Laboratories, validation, pharmaceutical, rapid microbial methods, rmm, outsource, contract, lab
Contacts
Celsis International
Jenny Woolway
jwoolway@celsis.com
+44 (0)20 7152 4459
Eurofins Lancaster Laboratories
Lisa Bamford
lbamford@lancasterlabs.com
717.656.2300 X1368
Permalink: http://www.me-newswire.net/news/9202/en
|